Introduction
Non-small cell lung cancer (NSCLC) is the major cancer killer disease worldwide in both males and females accounting for more than1.2 million deaths each year (Alberg et al., 2005) . NSCLC accounts for 75%-85% of all histotypes of lung cancer and the overall prognosis of NSCLC patients remains poor with a 5-year survival rate only 14% while 5-year survival rate less than 70% in stage I (Naruke, 1997; Spira et al., 2004 ). Cancer cells produce high level of their own peptide growth factors and this turn on the cellular proto-oncogenes (Goustin et al., 1986; Aaronson et al., 1991) . The epidermal growth factor (EGF) and its receptor (EGFR) play a central role in lung carcinogenesis. The EGF gene is located in chromosome 4q25-27 and its protein may activate DNA synthesis and promotes cellular proliferation by stimulating mitosis (Laurence and Carpenter, et al 1990) . EGF mRNA is 4.8- (Salomon et al., 1995) . The interaction between EGF and EGFR may be a risk factor for susceptibility and prognosis in various tumours, such as melanoma, glioblastoma and gastric cancer (Moulder et al., 2001) . EGFR signal promote cell proliferation, invasion, metastasis, angiogenesis, and inhibition of apoptosis (Tabernero et al., 2005) . The EGF A61G polymorphism is located in the 5'-untranslated region at position 61 and reported to functional influence on increase EGF production. Mononuclear cells from individuals with the AA genotype have been reported to decrease levels of EGF production than cells with GG genotype (Shahbazi et al., 2002) . Epidermal growth factor (EGF) is ligand which binds to EGFR receptors and transmits signal further, and it was observed in cancer cells EGFR signalling pathway is often deregulated and which increases proliferation, resistance to apoptosis, metastases and angio-genesis (Ciardiello et al., 2001; 2008; Hynes et al., 2005; Gan et al., 2012) . EGF ligand binding with its receptor (EGFR) pathway has been demonstrated to play a significant role in transducing growth signals to mitogen-activated protein kinase pathway, as well as the phosphatidylinositol 3-kinase causing NSCLC (Harris et al., 2003; Goto et al., 2005; Araujo et al., 2007) . EGF can also disrupt different pathways and contribute to metastasis due to intercalation of integrin α6β4 with EGFR, which can be important factor for cell migration (Araujo et al., 2007; Teixeira et al., 2008) . Shahbazi et al first time found that individuals homozygous for the 61AA genotype produced significantly low EGF level than the homozygous 61GG (p=0.0004) or heterozygous 61AG genotype (p=0.001) and suggested that high EGF synthesis is important to melanoma development (Shahbazi et al., 2002; Lim et al., 2005) . Many studies have evaluated the role of EGF A61G single nucleotide polymorphism. However, conflicting findings have been reported of EGF A61G polymorphism in lung cancer risk (Kang et al., 2007) . In the present study, we hypothesized that EGF (A61G) polymorphism may also be associated with cancer susceptibility, unfavourable clinical behaviour and risk of NSCLC in Indian population.
Materials and Methods

Cases and controls
Present study included histo-pathologically confirmed 100 newly diagnosed NSCLC (ADC) patients and 100 healthy controls. 3 ml of peripheral blood sample collected in EDTA vials from each subjects included in the study. This study was approved by the Institutional Ethics Committee of MAMC, New Delhi and written informed consent was obtained from all subjects. Patient follow-up was obtained through the hospital records and follow-up done from May 2013 to May 2015.
DNA extraction and genotype
Genomic DNA extraction was done by phenol chloroform method from blood samples collected in EDTA vials from NSCLC ADC cases as well as healthy controls. The +61 A/G polymorphism was analysed by allele specific PCR method with EGF +61A Forward 5' GCCCCAATCCAAGGGTTGTA3',EGF+61G Forward 5' GCCCCAATCCAAGGGTTGTG 3'and and reverse primer for both alleles is 5'GCCAAGGGAAGCCACAGGAAAG 3' (Kenneth K et al., 2008) . PCR was performed in 25 μl reaction volume containing 3 μl of 100 ng template DNA, 0.25 μl, 25 pmol each primer 2.5 μl, 10 mM dNTPs, 1. o C for 10 minutes. Amplified 206bp PCR products were separated by electrophoresis on a 2 % agarose gel containing ethidium bromide ( Figure  1 ).
Statistical analysis
Genotype frequencies between the cases and controls were evaluated using the Chi square test, Hardy-Weinberg equilibrium test used to check the allele frequency and values below 5 were analyzed by Fisher exact test. The associations between A61G genotypes and risk of NSCL cancer (ADC) were estimated by computing the odds ratios (ORs) and risk ratios (RRs) with 95 % confidence intervals (CIs). Kaplan-Meier methods were used to evaluate the relationship between A61G genotype and overall survival of NSCLC patients. All statistical analyses were performed using Graph Pad Prism 6.0 and SPSS 16.0.
Results
Study population
All demographic features of the subjects are depicted in table-1. In brief, total of 100 Non-small cell lung ADC patients and same number of healthy control were analyzed. Both NSCLC (ADC) cases and controls include 65% males and 35% females of age < 55 group (43 %) and >55group (57%) with mean ± SD in cases of 55.4+12.29 (range32-89 years) and controls of 54.25+10.82 (range 30-70 years). 75% patients were in stage IV, and 25% patients in stage III while 75% patients had distant metastases. Patients with different pathological grade, grade 1 (well differentiated) includes 41%, grade 2 (moderately differentiated) includes 23% and grade 3 (Poorly differentiated) includes 36% cases. We included smoker 44% as well as non smoker 56% with different smoking type as cigarette, bidi, and both, 15% cases smoked cigarette, 23% cases smoked bidi and 6% cases smoked both cigarette and bidi.
Genotype (A61G) distribution among Cases and Controls
The genotype and allele distributions of A61G in cases and controls are summarized in Table 2 and 5. We found statistically significant difference in genotype distribution of A61G in cases and healthy controls (p=0.0008). The frequency of G allele (fG) was to be higher among NSCLC (ADC) patients (0.55) compared to healthy controls (0.39) and the frequency of A allele (fA) in healthy controls was to be higher (0.61) compared to NSCLC cases (0.45).
EGF (A61G) genotype and NSCLC risk
Odds ratio and risk ratio with 95 % confidence intervals was calculated for each group to estimate the degree of association between the EGF (A61G 
EGF (A61G) genotype and NSCLC survival analysis
Survival analysis of 100 NSCLC (ADC) patients, based on genotype distribution was done and it was found that the mean follow-up time of the patients was 8.64 months (median 10.60; range 1-24.3 months) for the overall survival. NSCLC-related deaths events 86 (86% %) with mean follow-up time of 7.1months (median 7.35; range 1-15.8 months) and for the patients 
Discussion
Presence of the EGF +61G allele is a key point in the steps towards carcinogenesis by increasing serum EGF and stimulating proliferation, angiogenesis and metastasis (Zhang et al., 2010) . Interaction between serum EGF and its receptor (EGFR) is very important in NSCLC framework. EGF interaction with its receptor (EGFR) has been demonstrated to play a critical role in lung cancer carcinogenesis and tumour aggressiveness, mainly in NSCLC patients. The EGF/EGFR pathway transduces growth signals to mitogen-activated protein kinase pathway, phosphatidylinositol 3-kinase and other downstream pathways (Harris et al., 2003; Goto et al., 2005; Araujo et al., 2007; Zhang et al., 2010; HuLieskovan et al., 2011) . Costa et al in 2007 showed that the +61 G allele was associated with a high EGF expression level in vitro (Costa et al., 2007) . Wu et al in 2009 found a statistically significant association between EGF +61 G/G genotype and the +61 G allele with risk for colorectal cancer and pancreatic cancer risk development (Wu et al., 2009 ). Lim and colleagues conducted a study on schizophrenic patients and lung cancer patients in Korean population to analyse the EGF A61G polymorphism and observed an association of the EGF +61 A/G and EGF +61 G/G genotypes with lung cancer risk (OR 2.3, 95%CI 1.6082-3.3687) (Lim et al., 2005) . Meta-analysis studies also showed that EGF A61G polymorphism is associated with overall cancer risk (Zhang et al., 2010; Li et al., 2012) . The present data explored the association of EGF (A61G) polymorphism with risk and unfavourable clinical outcome of non-small cell lung cancer. We also observed a positive association between EGF +61 A/G polymorphism with NSCLC (ADC) patients. A significant difference was observed in distribution of EGF (A61G) genotype in NSCLC cases and controls. Our study, the first report from Indian population, suggested that homozygous EGF (+61)GG genotype is strongly associated with the risk of developing NSCLC ADC with approximately more than 3 fold increase than homozygous EGF (+61)AA genotype. EGF (+61) GG genotype was also been found to be an independent factor for unfavourable clinical outcome, However patients with GG genotype at higher risk for death than AA genotype of NSCLC patients. Increased risk of NSCLC (ADC) is also associated smoking behaviour and smoking status. EGF A61G polymorphism is also associated with other cancers, Ying Piao et al suggested that G allele and GG genotype of EGF A+61G (rs4444903) polymorphism has correlations with esophageal and colorectal cancer (Ying et al., 2013) . In a study, Vauleon et al (Vauleon et al., 2007) showed that the +61 A/G is functional polymorphism and the promoter with G allele had 40% more active than the A variant (p < 0.001). Costa et al. (Costa et al., 2007) also found that the G allele conferred higher risk for gliomas, glioblastomas, and oligodendrogliomas and it was significantly associated with increased risk for gliomas. The prevalence of the G/G genotype was significantly higher in melanoma patients, the G allele was present in nearly 66% of patients with malignant melanoma (odds ratio 4.9 [95% CI 2.3-10.2]; p < 0.0001) (Shahbazi et al., 2002) . Ichiro O et al in 2007 found a significant association between the highexpression homozygous G/G genotype of the EGF gene and shorter disease-free period and Malignant Melanoma specific survival compared to A/G and A/A carriers (Ichiro O et al., 2007) .
In conclusion, the present study we showed first time that EGF +61AG heterozygous and GG homozygous genotype are associated with reduced overall survival and risk of developing NSCLC (ADC) in the Indian population. EGF represents a novel prognostic marker to identify patients at higher risk for unfavourable clinical outcome. In addition, EGF (A61G) genotyping can be useful to decide specific EGF targeted therapy as well as in the management of NSCLC (ADC) patients.
